Ironwood’s stock drops 40% as short bowel syndrome drug shows mixed efficacy in PhIII
29 Feb 2024
Phase 3Clinical Result
Ironwood Pharmaceuticals’ GLP-2 analog hit the primary endpoint in a registrational short bowel syndrome study, but fell short of key secondary outcomes in a slightly larger patient subgroup, sending shares plummeting.
The Phase III STARS trial investigated once-weekly doses of the drug, apraglutide, against placebo in 164 adults with short bowel syndrome with intestinal failure (SBS-IF).
Around half of those dosed in the study had a stoma, while the remainder were “colon-in-continuity” patients, which was dubbed the “underserved majority” by VectivBio, the originator of apraglutide that Ironwood acquired last year in a $1 billion deal.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.